Terns Pharmaceuticals Appoints Biotech Executive Elona Kogan as Chief Legal Officer and Announces Upcoming CFO Transition

Company Leadership Changes - Elona Kogan has been appointed as the chief legal officer of Terns Pharmaceuticals, bringing over 20 years of experience in the life sciences sector, including pivotal roles in IPOs and commercialization at Seer, Inc. and other pharmaceutical companies [1][6] - Mark Vignola, the current chief financial officer, will leave the company in a planned transition, continuing until a successor is found, expected to be by the end of January 2025 [2][3] Company Pipeline and Development - Terns Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing small-molecule product candidates targeting serious diseases such as oncology and obesity [3][6] - The company's pipeline includes three clinical-stage development programs: an allosteric BCR-ABL inhibitor, a small-molecule GLP-1 receptor agonist, and a THR-β agonist, along with a preclinical GIPR modulator program [3]